APDN vs. MOB, JCSE, DGLY, CRKN, AREB, WATT, SPCB, AWX, VIEW, and MWG
Should you be buying Applied DNA Sciences stock or one of its competitors? The main competitors of Applied DNA Sciences include Mobilicom (MOB), JE Cleantech (JCSE), Digital Ally (DGLY), Crown ElectroKinetics (CRKN), American Rebel (AREB), Energous (WATT), SuperCom (SPCB), Avalon (AWX), View (VIEW), and Multi Ways (MWG). These companies are all part of the "industrial products" sector.
Applied DNA Sciences (NASDAQ:APDN) and Mobilicom (NASDAQ:MOB) are both small-cap industrial products companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends, valuation and community ranking.
Applied DNA Sciences received 290 more outperform votes than Mobilicom when rated by MarketBeat users. However, 100.00% of users gave Mobilicom an outperform vote while only 59.51% of users gave Applied DNA Sciences an outperform vote.
In the previous week, Mobilicom had 1 more articles in the media than Applied DNA Sciences. MarketBeat recorded 5 mentions for Mobilicom and 4 mentions for Applied DNA Sciences. Mobilicom's average media sentiment score of -0.20 beat Applied DNA Sciences' score of -0.31 indicating that Mobilicom is being referred to more favorably in the news media.
22.2% of Applied DNA Sciences shares are held by institutional investors. Comparatively, 13.6% of Mobilicom shares are held by institutional investors. 10.3% of Applied DNA Sciences shares are held by insiders. Comparatively, 7.2% of Mobilicom shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Applied DNA Sciences has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500. Comparatively, Mobilicom has a beta of 2.42, indicating that its stock price is 142% more volatile than the S&P 500.
Applied DNA Sciences presently has a consensus price target of $30.00, indicating a potential upside of 586.50%. Given Applied DNA Sciences' higher probable upside, research analysts plainly believe Applied DNA Sciences is more favorable than Mobilicom.
Mobilicom has a net margin of 0.00% compared to Applied DNA Sciences' net margin of -80.14%. Mobilicom's return on equity of 0.00% beat Applied DNA Sciences' return on equity.
Mobilicom has lower revenue, but higher earnings than Applied DNA Sciences.
Summary
Mobilicom beats Applied DNA Sciences on 9 of the 15 factors compared between the two stocks.
Get Applied DNA Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for APDN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Applied DNA Sciences Competitors List
Related Companies and Tools
